I though the closest for registrational study was Her-vaxx as the results of the Phase 2 trial for HER-Vaxx were considered successful in demonstrating both safety and efficacy, as well as a significant immunogenic response. These positive outcomes provided the rationale for moving forward with a registrational Phase 3 study, which can aim to further confirm these findings in a larger patient population and solidify the vaccine's efficacy and safety profile for potential approval.
Media Thread, page-15405
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $364.4M | |||
| Open | High | Low | Value | Volume |
| 4.9¢ | 5.0¢ | 4.8¢ | $519.1K | 10.60M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 70 | 9859318 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 316611 | 5 |
View Market Depth
| Last trade - 16.10pm 08/10/2024 (20 minute delay) ? |
| IMU (ASX) Chart |